In this older patient with T2DM, HFpEF, and other comorbidities, which class of medication is most appropriate--and guideline-recommended?
Diabetes Caution: FDA Warns of Risk of Missing Critical Alerts from Smartphone-Compatible Diabetes Devices
Hardware or software changes as well as user adjustments may disable or mute alerts for elevated glycemia, medication use, and other diabetes management essentials, the agency said.
Navigating Cardiovascular Complications of Obesity: Expert Insights for Primary Care
Listen to our latest podcast episode for details on top CVD risk factors to screen patients with obesity for, medications to help prevent CVD, and more.
Roche Receives FDA 510(k) Clearance for First US Blood Test Measuring Lp(a) in Molar Units
The Tina-quant® Lipoprotein (a) Gen.2 Molarity assay measures Lp(a) in molar units, providing a more accurate particle-based risk assessment than mass units.
Obesity & Type 2 Diabetes: An Expert Discussion
In our latest episode, 2 obesity experts discuss the importance of early intervention to reduce risk for complications, suggestions for managing patients in primary care, and more.
Furosemide Fails to Reduce Risk of Dangerous de novo Postpartum Hypertension: New Research
Close monitoring for dnPPHTN during the first 2 weeks post-delivery is highly recommended for women determined to be at high risk for the hypertensive disorder of pregnancy.
CVD Remains Leading Cause of Death in US: AHA 2025 Statistical Update
Cardiovascular disease is still the leading cause of death in the US, driven by rising rates of obesity, diabetes, and hypertension, according to new report.